natgillin/translations-raw huggingface dataset:
Every year, the European Medicines Agency reviewed additional information according to an agreed timetable on the quality, safety and efficacy of the vaccine.
Evropska agencija za zdravila bo vsako leto po dogovorjenem časovnem razporedu ponovno pregledala vse nove podatke o kakovosti, varnosti in učinkovitosti cepiva.
Both sheep and cattle will need a second injection three to four weeks later.
Ovce in govedo morajo tri do štiri tedne pozneje prejeti drugo injekcijo.
After vaccination, there can be a small swelling at the injection site lasting up to two weeks.
Po cepljenju lahko se lahko na mestu injiciranja pojavi manjša oteklina, ki traja do največ dva tedna.
The first injection is given at one month of age in animals that have never been exposed to the disease, and at two-and-a-half months if the animal's mother is already immune to the disease.
Prva injekcija se da mesec starim živalim, ki še nikoli niso bile izpostavljene bolezni, in dva meseca in pol starim mladičem mater, ki so že imune na bolezen.
The duration of protection was also investigated in studies using sheep and cattle and was found to be 12 months for both species.
Trajanje zaščite so proučevali tudi v študijah na ovcah in govedu, ugotovljeno pa je bilo, da traja ta za obe vrsti 12 mesecev.
The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat or milk used for human consumption.
Obdobje karence je čas, ki mora preteči po uporabi zdravila, preden se lahko žival zakolje in meso ali mleko uporabi za prehrano ljudi.
Results from a series of laboratory safety trials performed with vaccines of similar composition but of different bluetongue serotypes were also presented in order to extrapolate safety conclusions, as the vaccine was initially intended for use in an emergency situation.
Predloženi so bili tudi rezultati niza laboratorijskih preiskav varnosti s cepivi s podobno sestavo, vendar drugimi serotipi virusa modrega jezika, da bi ekstrapolirali zaključke o varnosti, saj je bilo cepivo prvotno namenjeno uporabi v nujnih primerih.
The studies also demonstrated that the vaccine can be used in pregnant sheep and cows.
Študije so pokazale tudi, da se cepivo lahko uporablja pri brejih ovcah in kravah.
The European Commission granted a marketing authorisation valid throughout the European Union for BTVPUR AlSap 8 on 17 March 2009.
Evropska komisija je dovoljenje za promet z zdravilom BTVPUR AlSap 8, veljavno po vsej Evropski uniji, odobrila dne 17. marca 2009.
Animals may show a temporary increase in body temperature, usually of no more than 1°C, in the 24 hours after vaccination.
Do 24 ur po cepljenju se lahko pri živalih pojavi prehodno povišanje telesne temperature, ki običajno ne presega 1°C.
Another laboratory study looked at the use of the vaccine in sheep aged three to four months.
V drugi laboratorijski študiji so proučevali uporabo cepiva na ovcah, starih od treh do štirih mesecev.
The CVMP considered that the benefits of BTVPUR AlSap 8 are greater than the risks and recommended that it be given a marketing authorisation.
CVMP je zaključil, da so koristi zdravila BTVPUR AlSap 8 večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
When it is given to sheep and cattle, the animals' immune system recognises the viruses as ‘foreign' and makes antibodies against them.
Ko ovce in govedo cepimo, njihov imunski sistem viruse prepozna kot „tujke“ in proti njim razvije protitelesa.
In 2012 the CVMP considered that the submitted data were adequate for the authorisation of BTVPUR AlSap 8 to convert to normal.
Leta 2012 je CVMP menil, da predloženi podatki zadostujejo, da se dovoljenje za promet z zdravilom BTVPUR AlSap 8 spremeni v običajno.
The studies showed that the vaccine is safe for sheep and cattle and that it prevents viraemia and reduces the signs of the disease in animals from one month of age that are infected with bluetongue virus serotype 8.
Študije so pokazale, da je cepivo varno za uporabo pri ovcah in govedu ter da preprečuje viremijo in zmanjšuje simptome bolezni pri živalih, starejših od enega meseca, ki so okužene s serotipom 8 virusa bolezni modrikastega jezika.
In the future, if the animals are exposed to the bluetongue virus their immune systems will be able to produce antibodies more quickly.
Ob ponovni izpostavitvi virusu bolezni modrikastega jezika v prihodnosti bo imunski sistem tako hitreje tvoril protitelesa.
The safety of the vaccine was studied in a number of laboratory safety studies carried out with BTVPUR AlSap in sheep and cattle using a high dose of the vaccine in animals of the minimum age.
Varnost cepiva so proučili v številnih laboratorijskih študijah varnosti, ki so jih opravili z uporabo cepiva BTVPUR AlSap 8 na govedu in ovcah, pri čemer so uporabili najvišji odmerek cepiva pri najmlajših živalih.
The efficacy of the vaccine in cattle was studied in a laboratory study using the vaccine in cattle from one month of age.
Učinkovitost cepiva pri govedu so proučili v laboratorijski preiskavi uporabe cepiva na govedu, starejšemu od enega meseca.
BTVPUR AlSap 8 was initially authorised under ‘exceptional circumstances'.
Zdravilo BTVPUR AlSap 8 je prvotno pridobilo dovoljenje za promet v „izjemnih okoliščinah“.
The vaccine is used to prevent viraemia (the presence of viruses in the blood) and reduce the signs of the disease caused by bluetongue virus serotype 8.
Cepivo se uporablja za preprečitev viremije (prisotnosti virusa v krvi) in zmanjšanje znakov bolezni, ki jo povzroča serotip 8 virusa modrega jezika.
Inactivated vaccine against bluetongue disease virus, serotype 8
inaktivirano cepivo proti virusu modrega jezika, serotip 8
The effects of maternally derived antibodies were investigated and the vaccine was shown to be effective in animals from 2.5 months of age.
Raziskali so tudi učinke maternalnih protiteles in ugotovljeno je bilo, da je cepivo učinkovito za živali, starejše od dveh mesecev in pol.
BTVPUR AlSap 8 contains bluetongue virus of one type (‘serotype 8').
Zdravilo BTVPUR AlSap 8 vsebuje en tip virusov modrega jezika („serotip 8“).
BTVPUR AlSap 8 is a vaccinethat is available as a suspension for injection.
Zdravilo BTVPUR AlSap 8 je cepivo, ki je na voljo v obliki suspenzije za injiciranje.
This means that it was not possible to obtain complete information about BTVPUR AlSap 8 at the time of the initial authorisation.
To pomeni, da ob prvotni odobritvi ni bilo mogoče pridobiti vseh podatkov o zdravilu BTVPUR AlSap 8.
No withdrawal period for meat and milk with BTVPUR AlSap 8 is necessary (zero days withdrawal period).
Karenca za meso in mleko po jemanju zdravila BTVPUR AlSap 8 ni potrebna (karenca nič dni).
BTVPUR AlSap 8 is used in sheep and cattle to protect them against bluetongue disease, an infection caused by the bluetongue virus which is transmitted by midges.
Zdravilo BTVPUR AlSap 8 se uporablja pri ovcah in govedu za zaščito pred boleznijo modrega jezika, tj. okužbo, ki jo prenašajo trzače, povzroča pa jo virus modrega jezika.
BTVPUR AlSap 8 is a vaccine.
Zdravilo BTVPUR AlSap 8 je cepivo.
BTVPUR AlSap 8 contains bluetongue viruses that have been inactivated so that they cannot cause the disease.
Zdravilo BTVPUR AlSap 8 vsebuje viruse modrega jezika, ki so inaktivirani in ne morejo povzročiti bolezni.
What benefit has BTVPUR AlSap 8 shown during the studies?
Kakšne koristi je zdravilo BTVPUR AlSap 8 izkazalo med študijami?
Other information about BTVPUR AlSap 8:
Druge informacije o zdravilu BTVPUR Alsap 8:
It contains inactivated (killed) bluetongue serotype 8 virus.
Vsebuje inaktivirane (uničene) viruse modrega jezika, serotip 8.
What is the risk associated with BTVPUR AlSap 8?
Kakšna tveganja so povezana z zdravilom BTVPUR AlSap 8?
Why has BTVPUR AlSap 8 been approved?
Zakaj je bilo zdravilo BTVPUR AlSap 8 odobreno?
What is BTVPUR AlSap 8?
Kaj je zdravilo BTVPUR AlSap 8?
What is BTVPUR AlSap 8 used for?
Za kaj se zdravilo BTVPUR AlSap 8 uporablja?
How has BTVPUR AlSap 8 been studied?
Kako je bilo zdravilo BTVPUR AlSap 8 raziskano?
How does BTVPUR AlSap 8 work?
Kako zdravilo BTVPUR AlSap 8 deluje?
The Member States shall ensure that the Marketing Authorisation Holder (MAH) provides physicians who are expected to prescribe/use Leflunomide ratiopharm with a physician educational pack containing the following:
Država članica mora zagotoviti, da bo imetnik dovoljenja za promet z zdravilom poskrbel, da bodo vsi zdravniki, za katere se pričakuje, da bodo zdravilo Leflunomide ratiopharm predpisovali ali uporabljali, dobili izobraževalno gradivo, ki vsebuje:
The information provided in the Physician Leaflet should provide information on dose reduction, discontinuation and wash out procedures in the event of raised ALT.
Informacije v navodilu za zdravnika morajo vsebovati podatke o prilagajanju odmerka, prenehanju zdravljenja in postopkih za izplavljanje v primeru zvišanih vrednosti ALT.
These measures will help to protect the environment.
S temi ukrepi boste pomagali ohranjati okolje.
• change or absence of menstrual period*
• sprememba ali izostanek menstruacije*;
TTP=time to progression; “ne” indicates that it could not be estimated or it was not yet reached.
ČDN = čas do napredovanja; "no" pomeni, ni bilo mogoče oceniti ali še ni doseženo.
• allergic reactions (see above)
• alergijske reakcije (glejte zgoraj);
Overall survival (Primary endpoint)
Celotno preživetje (primarna končna točka)
Vial 24 months
Viala 24 mesecev
Median duration of follow-up was 77 months.
Mediano trajanje spremljanja je bilo 77 mesecev.
Shake well for complete solubilisation of powder (the powder will be dissolved in less than 90 seconds).
Dobro pretresite, da se prašek popolnoma raztopi (prašek se bo raztopil v manj kot 90 sekundah).
However, the distribution of OS was not significantly different between the 2 groups.
Toda porazdelitev celotnega preživetja se med obema skupinama ni značilno razlikovala.
The expiry date refers to the last day of that month.
Datum preteka roka uporabe se nanaša na zadnji dan meseca.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 10 May 2010
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Date of first authorisation: 10 maj 2010
The effect appears to be less pronounced than in patients with 1-3 positive nodes.
Kaže, da je učinek manj izrazit kot pri bolnicah z 1-3 pozitivnimi bezgavkami.
From a microbiological point of view, the reconstituted solution should be used immediately.
Iz mikrobiološkega vidika pa je treba pripravljeno raztopino uporabiti takoj.
You will be given Docefrez by a healthcare professional in the hospital.
Zdravilo Docefrez vam bo v bolnišnici dal strokovni zdravstveni delavec.
*: Corrected for multiple comparisons and adjusted for stratification factors (stage of disease and region of treatment), based on evaluable patient population.
*: Korigirano za mnogokratne primerjave in prilagojeno za stratifikacijske faktorje (stadij bolezni in predel zdravljenja) na podlagi ocenljive populacije bolnikov.
An appropriate aseptic technique should be used for all steps.
V vseh korakih uporabite ustrezno aseptično tehniko.
Side effects marked with “*” have been reported when Docefrez was given in combination.
Stranski učinki označeni z “*” so bili opaženi v primerih, ko je Docefrez bil predpisan v kombinaciji.
Elderly patients treated with TCF should be closely monitored.
Starejše bolnike, ki dobivajo TCF, je treba natančno nadzirati.
Medium time to progression (weeks):
Mediana časa do napredovanja (tedni):
Pharmacotherapeutic group: Taxanes, ATC Code: L01CD02
Farmakoterapevtska skupina: taksani, oznaka ATC: L01CD02
Please tell your doctor or nurse if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Zdravnika ali medicinsko sestro opozorite, če uživate ali ste nedavno uživali kakšna druga zdravila, vključno z zdravili, ki jih prejmete brez recepta.
If the patient continues to experience these reactions at 60 mg/m2, the treatment should be discontinued.
Če bolnik tudi pri odmerku 60 mg/m še doživlja te reakcije, je treba zdravljenje prekiniti.
Post-marketing experience
Pomarketinške izkušnje
• bleeding from the nose
• krvavitve iz nosu;
• loss of appetite (anorexia), weight gain or loss*
• izguba apetita (anoreksija), izguba ali pridobivanje teže*.
An interim analysis was performed with a median follow up of 55 months.
Narejena je bila vmesna analiza z mediano 55-mesečnim spremljanjem.
When Docefrez is given in combination with other anti-cancer medicines, the frequency or severity of some side effects may increase.
Če je Docefrez predpisan v kombinaciji z drugimi zdravili proti raku, se lahko resnost ali pogostost stranskih učinkov poveča.
Your doctor will calculate your dose according to your body surface area in square metres (depends on weight and height) and your general condition.
Zdravnik bo izračunal vaš dnevni odmerek glede na površino vašega telesa v m² (odvisno od telesne mase in višine) in vašega splošnega stanja.
Docefrez vials should be stored in a refrigerator.
Docefrez viale morate hraniti v hladilniku.
Medicines should not be disposed of via wastewater or household waste.
Zdravil ne smete odstranjevati v odpadne vode ali gospodinjske odpadke.
This medicinal product must not be mixed with other medicinal products except those mentioned in section
Zdravila ne smemo mešati z drugimi zdravili, razen s tistimi, ki so omenjena v poglavju 6.6
An effective method of contraception should be used during treatment.
Med zdravljanjem je treba uporabljati učinkovit način kontracepcije.
≥35 years
≥35 let
Each carton contains:
V vsakem pakiranju je :
• swelling caused by fluids from the lymph nodes spreading to uncommon places
• otekline zaradi tekočin iz limfnih žlez, ki se širijo na neobičajnih mestih;
• fever*: tell your doctor or nurse immediately
• povišana telesna temperatura*: nemudoma obvestite zdravnika ali medicinsko sestro;
The MAH must ensure that the system of pharmacovigilance, as described in version 6 (dated January 2010) presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.
Imetnik dovoljenja za promet mora zagotoviti, da je sistem farmakovigilance kot je opisan v različici 6 (z datumom Januar 2010) , predstavljen v Modulu 1.8.1 vloge za pridobitev dovoljenja za promet z zdravilom, vzpostavljen in da deluje, preden da zdravilo v promet in toliko časa, kolikor bo zdravilo v uporabi.
However, given that it can cause dizziness, tiredness and fainting, you should not drive or use machines if you experience any of these side effects.
Kljub temu, glede na to, da lahko povzroči vrtoglavico, utrujenost in omedlevico, v primeru da se pojavijo ti neželeni učinki ne vozite ali uporabljajte strojev.
It is administered through a drip into a vein (intravenous infusion) for about one hour.
Daje se v žilo (intravenozna infuzija) približno eno uro.
White lyophilised powder.
Beli liofiliziran prašek.
Like all medicines, Docefrez can cause side effects, although not everybody gets them.
Kot vsa zdravila lahko Docefrez povzroči neželene učinke, ki pa se ne pojavijo pri vseh osebah.
There are no studies on the effects of Docefrez on the ability to drive and use machines.
Ni raziskav o vplivu Docefreza na zmožnost vožnje in uporabe strojev.
The beneficial effect of TAC was not proven in patients with 4 and more positive nodes (37% of the population) at the interim analysis stage.
Ugodni učinek TAC ni bil dokazan pri bolnicah s 4 ali več pozitivnimi bezgavkami (37 % populacije) na stopnji vmesne analize.
Your doctor may change the dose and/or frequency of administration depending on the results of your blood tests, your general condition and the occurence of certain side effects.
Vaš zdravnik bo morda spremenil odmerek in/ali pogostost odmerjanja glede na rezultate krvnih preiskav, vaše splošno stanje in pojav določenih neželenih učinkov.
Store in a refrigerator (2ºC - 8ºC).
Hranite v hladilniku (2ºC - 8ºC).
The performance status scale, for head and neck (PSS-HN) subscales designed to measure understandability of speech, ability to eat in public, and normalcy of diet, was significantly in favor of TPF as compared to PF.
Lestvica stanja zmogljivosti s podlestvicama za glavo in vrat (PSS-HN), namenjenima merjenju razumljivosti govora, sposobnosti uživanja hrane na javnem mestu in normalnosti hrane, je signifikantno govorila v korist TPF v primerjavi s PF.
The safety and efficacy of docetaxel in nasopharyngeal carcinoma in children aged 1 month to less than 18 years have not yet been established.
Varnost in učinkovitost zdravila docetaksela za zdravljenje nazofaringealnega karcinoma pri otrocih od 1 meseca do manj kot 18 let starosti nista ugotovljeni.
• CONDITIONS OF RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO
For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.
Za pogoje shranjevanje pripravljenega in razredčenega zdravila glejte poglavje 6.3.
(see sections 4.4 and 4.8).
(glejte poglavje 4.4).
The infusion should be used within 4 hours below 25 ºC.
Infuzijo morate uporabiti v roku 4 ur (pod 25 ºC).
The incidence of serious adverse events was higher in the elderly patients compared to younger patients.
Incidenca resnih neželenih učinkov je bila pri starejših bolnikih večja kot pri mlajših.
You should usually receive your Docefrez infusion every three weeks.
Infuzijo Docefrez-a običajno prejmete vsake tri tedne.
4.1.4 Remove the syringe and needle and shake well for complete solubilisation of powder.
4.1.4 Odstranite brizgo in iglo ter dobro pretresite, za popolno solubilizacijo praška.
For combination with trastuzumab, adverse events (all grades) reported in ≥ 10% are displayed.
Pri kombinaciji s trastuzumabom so predstavljeni neželeni učinki (vseh stopenj) poročani v > 10 %.
75 mg/m2 (see sections 4.4 and 5.2).
75 mg/m2 (glejte poglavji 4.4 in 5.2).
Each pack contains: 1 powder vial and 1 solvent vial.
Vsako pakiranje vsebuje: 1 vialo s praškom in 1 vialo z vehiklom.
• decreased number of platelets (increased risk of unexpected bleedings)
• znižano število trombocitov (povečana nevarnost nepričakovane krvavitve);
Intravenous use, after reconstitution and dilution.
Intravenozna uporaba, po pripravi in razredčitvi.
Docetaxel plus trastuzumab1 n=92
Docetaksel in trastuzumab1 n = 92
The application is based on a reference medicinal product for which no safety concerns requiring additional risk minimization activities have been identified.
Vloga temelji na referenčnem zdravilu, za katerega niso bila ugotovljena varnostna vprašanja,
Symptoms such as early abdominal pain and tenderness, fever, diarrhoea, with or without neutropenia, may be early manifestations of serious gastrointestinal toxicity and should be evaluated and treated promptly.
Simptomi kot so abdominalne bolečine in občutljivost, zvišana telesna temperatura, driska z ali brez nevtropenije, so lahko zgodnja manifestacija resne gastrointestinalne toksičnosti ter jih je potrebno nemudoma ovrednotiti in zdraviti.
The main test method used to determine HER2 positivity in this pivotal study was immunohistochemistry (IHC).
HER2-pozitivnosti v tej odločilni študiji je bila imunohistokemija (IHK).
4.1.3 Inject the entire contents of the syringe into the corresponding Docefrez vial.
4.1.3 Vbrizgajte celotno vsebino injekcijske brizge v ustrezno vialo Docefreza.
What Docefrez looks like and contents of the pack
Kakšen je Docefrez in vsebina pakiranja
Before each Docefrez dose, you will have blood tests to check that your blood cell counts and liver function are adequate.
Pred vsakim odmerkom Docefrez boste imeli pregled krvi za preverjanje ali je število vaših rdečih krvnih celic in delovanje jeter primerno.
Docetaxel1 n=94
Docetaksel1 n = 94
Survival data, median time to progression and response rates for two arms of the study are illustrated in the following table.
Podatke o preživetju, mediano časa do napredovanja in delež odziva v dveh krakih te raziskave prikazuje naslednja preglednica:
• dripping or running nose; inflammation of the throat and nose*
• kapljanje iz nosu; vnetje grla in nosu*;
Detailed information on this medicine is available on the European Medicines Agency web site: ://www.ema.europa.eu
Podrobne informacije o zdravilu je na voljo na spletni strani Evropske agencije za zdravila (EMA): ://www.ema.europa.eu
Docefrez is incompatible with PVC equipment or devices.
Docefrez ni združljiv s PVC opremo ali napravami.
Dry skin; Desquamation
Suha koža, luščenje
Acute leukaemia / Myelodysplastic syndrome
Akutna levkemija / mielodisplastični sindrom
• raised liver enzymes (in blood tests)
• krvavitve; • povišani jetrni encimi (v krvnih testih);
Congestive Heart Failure (CHF) has been reported in 18 of 1276 patiens during the follow-up period.
Opisano je bilo tudi kongestivno srčno popuščanje pri 18 od 1276 bolnicah v obdobju spremljanja.
The secondary endpoint, PFS, demonstrated a 29% risk reduction of progression or death and a 22 month improvement in median PFS (35.5 months for TPF and 13.1 for PF).
(PBN), je pokazala 29 % zmanjšanje tveganja za napredovanje ali smrt ter 22-mesečno izboljšanje medianega PBN (35,5 mesecev pri TPF in 13,1 pri PF).
Overall, quality of life (QoL) and clinical benefit results consistently indicated improvement in favor of the TCF arm.
V celoti pa rezultati kakovosti življenja in klinične koristi dosledno kažejo izboljšanje v kraku s TCF.
In non clinical studies, docetaxel has genotoxic effects and may alter male fertility (see section 5.3).
V nekliničnih študijah je bilo dokazano, da ima docetaxel genotoksične učinke in lahko vpliva na plodnost moških (glejte oddelek 5.3).
Do not use any PVC equipment or device.
Ne uporabljajte opreme ali naprav iz PVC-ja.
If you have any further questions on the use of this medicine, ask your doctor or nurse.
V primeru dodatnih vprašanj o uporabi izdelka, se obrnite na zdravnika ali medicinsko sestro.
The median cumulative dose to treatment discontinuation was more than 1,000 mg/m2 and the median time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks).
Mediani kumulativni odmerek do prekinitve zdravljenja je bil več kot 1.000 mg/m2 in mediani čas do izginotja zastoja tekočine 16,4 tedna (razpon od 0 do 42 tednov).
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or nurse.
Če kateri izmed stranskih učinkov postane resnejši ali če opazite stranske učinke, ki niso navedeni v tej brošuri, povejte zdravniku ali medicinski sestri.
Patients treated with TPF experienced significantly less deterioration of their Global health score compared to those treated with PF (p=0.01, using the EORTC QLQ-C30 scale).
Pri bolnikih, zdravljenih s TPF, se je lestvica globalnega zdravja signifikantno manj poslabšala kot pri tistih, ki so bili zdravljeni s PF (p = 0,01, uporabljena je bila lestvica EORTC QLQ-C30).
• headache* , insomnia*
• glavobol* , nespečnost*;
• feeling of numbness or pins and needles, taste disturbances (due to nerve damage)
• občutek otrplosti ali mravljincev, motnje okusa (zaradi poškodovanih živcev);
Reduced tolerance of docetaxel may occur, even at lower doses.
Celo pri zmanjšanih odmerkih se lahko pojavi zmanjšanje tolerance docetaksela.
- If you have any further questions, ask your doctor or nurse.
Če imate dodatna vprašanja, se posvetujte z zdravnikom ali z bolnišničnim farmacevtom.
Tell your doctor if you have: - heart problems - liver problems - kidney problems
Zdravnika opozorite v primeru: težav s srcem težav z jetri težav z ledvicami
Based on the required dose for the patient expressed in mg, aseptically withdraw the corresponding volume from the appropriate number of reconstituted solutions using graduated syringes fitted with a needle.
Odvisno od potrebnega odmerka za pacienta v mg, aseptično izvlecite potrebno količino iz ustreznega števila pripravljenih raztopin s pomočjo oštevilčene brizge z iglo.